SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Gliatech (GLIA) -- Ignore unavailable to you. Want to Upgrade?

To: M. P. McNamara, Jr. M.D. who wrote (944)9/27/1999 9:45:00 AM
From: scaram(o)uche  Respond to of 2001
 
Gliatech has initiated drug development programs aimed at developing novel inhibitors of these two glycine transporters. The Company has identified prototype inhibitors of GlyT1 and is investigating these and related compounds for their potential utility in the treatment of schizophrenia and dementia.

Cool. Go GLIA!



To: M. P. McNamara, Jr. M.D. who wrote (944)9/27/1999 4:38:00 PM
From: Biotech Jim  Read Replies (1) | Respond to of 2001
 
How is this glycine transporter program impacted by the patent that Trophix (bought out by and now owned by Allelix) has on this type of discovery program?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News